The Dosing Problem: Why Generic Supplement Labels Get the Dose Wrong

Every supplement label that lists a single serving size for "adults" is making an assumption: that all adults require the same amount to achieve a similar effect. Pharmacokinetic research accumulated over decades challenges that assumption.

The regulatory framework governing supplement labeling in the United States — the Dietary Supplement Health and Education Act of 1994 (DSHEA) and subsequent FDA guidance — does not require manufacturers to establish that a stated dose achieves a defined clinical outcome in a defined population. Labels are required to be truthful and not misleading, but dose selection is largely at the manufacturer's discretion. The result is that many doses on the market are derived from historical convention, extrapolation from food content studies, or the doses used in clinical trials that may not represent general populations.

The VITAL trial (Manson et al., New England Journal of Medicine, 2019 — PMID 30415629), which enrolled approximately 25,000 adults, documented how wide the distribution of individual vitamin D3 responses is even at a fixed 2,000 IU/day dose. Despite identical supplementation, achieved serum 25(OH)D levels varied substantially — with a meaningful fraction of participants remaining below 30 ng/mL (a commonly cited adequacy threshold) while others who were already replete at baseline showed only modest increments. Body weight, baseline status, and individual variation in absorption and binding-protein genetics each contribute to that spread.

This kind of variability is not unique to vitamin D. It is a consistent finding across water-soluble vitamins, minerals, and botanical extracts whenever controlled PK studies measure individual responses rather than group means.

Published pharmacokinetic research has identified five categories of individual variation that reliably influence how much of an orally dosed supplement reaches systemic circulation and target tissues.

**1. Body weight and volume of distribution.** For supplements that distribute into total body water or fat mass, a fixed dose delivers a lower concentration per unit mass in a larger or more adipose individual. A 2012 study by Drincic et al. in Obesity (PMID 22262154) analyzed vitamin D status and body composition data in 686 adults and found that body weight explained the majority of the low vitamin D status associated with obesity — not sequestration in fat tissue as previously hypothesized, but volumetric dilution: vitamin D distributes throughout a larger compartment, lowering the achieved concentration per given dose. The authors modeled a hyperbolic relationship between body weight and serum 25(OH)D that accounted for most of the obesity-related vitamin D deficit.

**2. Baseline nutrient status.** Fractional absorption of many minerals is inversely regulated — the gut absorbs more when stores are depleted and less when stores are replete. A 1991 metabolic study by Taylor et al., published in the American Journal of Clinical Nutrition (PMID 2000832), directly measured zinc absorption using stable-isotope tracers in five healthy men under controlled dietary zinc depletion. The investigators found that fractional zinc absorption increased from approximately 38% at baseline to approximately 93% after a period of depletion — a greater-than-twofold increase triggered purely by falling zinc status. Same dose, same form, dramatically different absorption based solely on baseline status.

**3. Fat intake at the time of dosing.** Fat-soluble supplements (vitamins D, E, K, A; CoQ10; omega-3 fatty acids) require dietary fat for micellar emulsification and lymphatic absorption. A 2015 study by Dawson-Hughes et al. in the Journal of the Academy of Nutrition and Dietetics found that vitamin D3 absorption was approximately 32% higher when taken with a high-fat meal compared to a fat-free meal in healthy adults. The standard label direction to "take daily" does not specify co-ingestion conditions.

**4. Gastric acid and dissolution.** Inorganic mineral salts (calcium carbonate, magnesium oxide) require an acidic environment for dissolution. A 1985 study by Recker, published in the New England Journal of Medicine, found that calcium carbonate absorption was severely impaired — reduced by approximately 80% — in patients with achlorhydria (absent gastric acid) compared to controls. Age-related decline in gastric acid production is common in adults over 60, affecting a large segment of supplement users.

**5. Genetic variation in transport and metabolism.** Single-nucleotide polymorphisms in genes encoding nutrient transporters, metabolic enzymes, and binding proteins measurably alter dose response. The MTHFR C677T variant, present in approximately 10% of the population in homozygous form, reduces 5,10-methylenetetrahydrofolate reductase enzyme activity by approximately 70% (Frosst et al., Nature Genetics, 1995 — PMID 7647779), impairing conversion of folic acid to the active methylfolate form and changing the effective dose required to achieve equivalent folate status.

For a subset of nutrients — primarily those with established Dietary Reference Intake (DRI) values — the dose on a supplement label may be derived from population-level DRI data published by the National Academies of Sciences, Engineering, and Medicine. DRI values are themselves population averages, calculated to meet the needs of 97–98% of healthy individuals in a defined age/sex group. They are deliberately set at levels high enough to cover most of the population's variability — they are not individually calibrated doses.

For many supplement categories where DRI values do not exist — botanical extracts, many amino acids, specialized metabolites — dose selection is made by the manufacturer. DSHEA does not require that a specific dose be established through controlled clinical trials before a product reaches market. The result is that doses across products in these categories can vary substantially even when products claim the same ingredient and target population.

The absence of a mandated evidence base for dose selection means that the milligrams on the label may or may not reflect a dose studied in clinical trials, and even if they do, the trials may not have measured individual variation in response.

For any supplement where the effective dose range is narrower than the population variability in absorption and distribution, the same label dose will simultaneously underdose some people and overdose others.

Vitamin D illustrates this at clinical scale. A large randomized supplementation study — the VITAL trial (Manson et al., New England Journal of Medicine, 2019 — PMID 30415629) — tested 2,000 IU/day of vitamin D3 in approximately 25,000 adults. The mean serum 25(OH)D level in the supplementation group was approximately 41 ng/mL. But the distribution of individual responses was wide; a meaningful proportion of participants remained below 30 ng/mL (a commonly cited adequacy threshold) despite consistent supplementation. Meanwhile, participants with already-replete baseline status experienced smaller increases from the same dose.

A 2,000 IU label dose simultaneously left some individuals insufficient and represented over-supplementation for others who were already replete — at the same dose, in the same trial.

This is not a failure of the study design; it is the expected consequence of applying a population average dose to individuals with differing baselines, body compositions, and absorption efficiencies.

Consult your physician before modifying supplement doses, particularly if you have a chronic health condition, are pregnant, or are taking medications. Some supplements have established upper tolerable intake levels above which adverse effects have been documented.

For dosing to be calibrated to an individual rather than an average, a minimum of three inputs are needed:

1. **The individual's baseline status.** For most nutrients, absorption rates and utilization are regulated relative to existing stores. A clinically validated baseline measurement (blood level for vitamins D and B12; red blood cell status for folate and magnesium; urinary biomarkers for zinc) tells you where you are starting from.

2. **The individual's absorption phenotype.** For minerals especially, fractional absorption varies substantially based on gut health, gastric acid production, and competing minerals in the diet. This is rarely assessed outside research settings.

3. **The form and co-ingestion conditions.** The specific chemical form of a supplement determines elemental density and dissolution characteristics; co-ingestion conditions (fed/fasted, fat content) determine absorption efficiency for fat-soluble compounds.

Absent these inputs, a single-number label dose is a guess informed by population averages — a useful starting point, but not a personalized recommendation.

The FormulaForge dose model — which classifies doses into Low, Minimum Viable, Functional, and Clinical zones using ingredient-specific pharmacokinetic data — is designed to give context to where a chosen dose sits relative to the range documented in clinical research. See <a href="/learn/dose-ranges">How FormulaForge defines dose ranges</a> for the full zone model and worked examples.